Patents by Inventor Xianqi Kong

Xianqi Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE
    Publication number: 20220202778
    Abstract: There are provided methods for treating or preventing a cerebrovascular disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an isotope-enriched compound or a pharmaceutical composition thereof, where the isotope-enriched compound has the general Formula (I) or is a pharmaceutically acceptable salt or ester thereof: R1R2X—CR2—CH2—CH2—SO3H??(I).
    Type: Application
    Filed: November 10, 2021
    Publication date: June 30, 2022
    Inventors: Jiasheng LU, Jiamin GU, Xianqi KONG
  • CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO)) -3, 3-DIDEUTERIUM-1-PROPANESULFONIC ACID, PREPARATION METHOD AND USES THEREOF
    Publication number: 20220144766
    Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.
    Type: Application
    Filed: August 18, 2021
    Publication date: May 12, 2022
    Inventors: Jiasheng LU, Jiamin GU, Daiqiang HU, Xianqi KONG
  • Prodrugs of a CDK inhibitor for treating cancers
    Patent number: 11225497
    Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: January 18, 2022
    Assignees: RISEN (SUZHOU) PHARMA TECH CO., LTD., SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
    Inventors: Jiasheng Lu, Jiamin Gu, Gang Chen, Xiaolin Zhang, Feng Zhou, Xianqi Kong
  • A CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO) -1-PROPANESULFONIC ACID
    Publication number: 20220002239
    Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-1-propanesulfonic acid, preparation method and uses thereof.
    Type: Application
    Filed: October 30, 2019
    Publication date: January 6, 2022
    Inventors: Jiasheng LU, Jiamin GU, Xiang JI, Xinyong LV, Juan PENG, Xianqi KONG
  • STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF
    Publication number: 20220002285
    Abstract: There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.
    Type: Application
    Filed: March 25, 2021
    Publication date: January 6, 2022
    Inventors: Jiasheng LU, Jiamin GU, Xiang JI, Dongqing ZHU, Xiaolin HE, Xianqi KONG
  • METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID
    Publication number: 20210386693
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: April 26, 2021
    Publication date: December 16, 2021
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
  • Crystalline form of 3-((L-valyl)amino))-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof
    Patent number: 11186543
    Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: November 30, 2021
    Assignee: RISEN (SUZHOU) PHARMA TECH CO., LTD.
    Inventors: Jiasheng Lu, Jiamin Gu, Daiqiang Hu, Xianqi Kong
  • ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF
    Publication number: 20210347731
    Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-? related diseases, such as Alzheimer's disease.
    Type: Application
    Filed: January 4, 2021
    Publication date: November 11, 2021
    Inventors: Jiasheng LU, Jiamin GU, Xinyong LV, Guowei SONG, Dongdong WU, Daiqiang HU, Jun GU, Gang CHEN, Xiang JI, Xiuchun ZHANG, Jinchao AI, Xianqi KONG
  • Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
    Patent number: 11020360
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 1, 2021
    Assignee: Bellus Health Inc.
    Inventors: Xianqi Kong, Mohamed Atfani, Benoit Bachand, Abderrahim Bouzide, Stephane Ciblat, Sophie Levesque, David Migneault, Isabelle Valade, Xinfu Wu, Daniel Delorme
  • CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20210139526
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
    Type: Application
    Filed: December 23, 2020
    Publication date: May 13, 2021
    Inventors: Jiasheng LU, Jiamin GU, Gang CHEN, Feng ZHOU, Qiguo ZHANG, Xuli WANG, Xiang JI, Lin WANG, Xianqi KONG
  • Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof
    Patent number: 10954188
    Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-? related diseases, such as Alzheimer's disease.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: March 23, 2021
    Assignee: RISEN (SUZHOU) PHARMA TECH CO., LTD.
    Inventors: Jiasheng Lu, Jiamin Gu, Xinyong Lv, Guowei Song, Dongdong Wu, Daiqiang Hu, Jun Gu, Gang Chen, Xiang Ji, Xiuchun Zhang, Jinchao Ai, Xianqi Kong
  • GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS
    Publication number: 20210079033
    Abstract: There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.
    Type: Application
    Filed: December 17, 2018
    Publication date: March 18, 2021
    Inventors: Xianqi KONG, Jiasheng LU, Jiamin GU, Xiang JI, Daiqiang HU, Xiuchun ZHANG, Xinyong LV, Jinchao AI, Dongdong WU, Lin WANG, Dongqing ZHU, Xiaolin HE
  • PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER
    Publication number: 20210078970
    Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers.
    Type: Application
    Filed: August 28, 2020
    Publication date: March 18, 2021
    Inventors: Jiasheng LU, Jiamin GU, Gang CHEN, Qiguo ZHANG, Chengyong SUN, Xianqi KONG
  • CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO)) -3, 3-DIDEUTERIUM-1-PROPANESULFONIC ACID, PREPARATION METHOD AND USES THEREOF
    Publication number: 20210053914
    Abstract: The present invention relates to a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof.
    Type: Application
    Filed: December 28, 2018
    Publication date: February 25, 2021
    Inventors: Jiasheng LU, Jiamin GU, Daiqiang HU, Xianqi KONG
  • CD73 inhibitors and pharmaceutical uses thereof
    Patent number: 10881681
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 5, 2021
    Assignee: RISEN (SUZHOU) PHARMA TECH CO., LTD.
    Inventors: Jiasheng Lu, Jiamin Gu, Dongdong Wu, Gang Chen, Chengyong Sun, Xiang Ji, Lin Wang, Feng Zhou, Xiuchun Zhang, Xianqi Kong
  • Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
    Patent number: 10857109
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: December 8, 2020
    Assignee: Bellus Health, Inc.
    Inventors: Xianqi Kong, Mohamed Atfani, Benoit Bachand, Abderrahim Bouzide, Stephane Ciblat, Sophie Levesque, David Migneault, Isabelle Valade, Xinfu Wu, Daniel Delorme
  • PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS
    Publication number: 20200339615
    Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 29, 2020
    Inventors: Jiasheng LU, Jiamin GU, Gang CHEN, Xiaolin ZHANG, Feng ZHOU, Xianqi KONG
  • METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID
    Publication number: 20200253897
    Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Inventors: Xianqi KONG, Mohamed ATFANI, Benoit BACHAND, Abderrahim BOUZIDE, Stephane CIBLAT, Sophie LEVESQUE, David MIGNEAULT, Isabelle VALADE, Xinfu WU, Daniel DELORME
  • ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES AND USES THEREOF
    Publication number: 20200223793
    Abstract: There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-? related diseases, such as Alzheimer's disease.
    Type: Application
    Filed: October 17, 2019
    Publication date: July 16, 2020
    Inventors: Jiasheng LU, Jiamin GU, Xinyong LV, Guowei SONG, Dongdong WU, Daiqiang HU, Jun GU, Gang CHEN, Xiang JI, Xiuchun ZHANG, Jinchao AI, Xianqi KONG
  • CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20200078388
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 12, 2020
    Inventors: Jiasheng LU, Jiamin GU, Dongdong WU, Gang CHEN, Chengyong SUN, Xiang JI, Lin WANG, Feng ZHOU, Xiuchun ZHANG, Xianqi KONG